Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.

[1]  E. Smit,et al.  Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors , 2018, Nature Communications.

[2]  Charles M. Rudin,et al.  Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer , 2018, Clinical Cancer Research.

[3]  S. C. Wang,et al.  OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer , 2018, Journal of Thoracic Oncology.

[4]  P. Paik,et al.  OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients with Advanced NSCLC and MET Exon 14-Skipping Mutations , 2018, Journal of Thoracic Oncology.

[5]  H. Groen,et al.  Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Ou,et al.  Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient. , 2018, Lung cancer.

[7]  C. Paweletz,et al.  Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer , 2018, Clinical Cancer Research.

[8]  F. Peng,et al.  Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping. , 2017, Lung cancer.

[9]  Angela N. Brooks,et al.  MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma. , 2017, Cancer research.

[10]  P. Jänne,et al.  Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models , 2017, Clinical Cancer Research.

[11]  Elizabeth A. Tovar,et al.  MET in human cancer: germline and somatic mutations. , 2017, Annals of translational medicine.

[12]  V. Miller,et al.  Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Yi-long Wu,et al.  Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[14]  M. Stratton,et al.  Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations , 2017, bioRxiv.

[15]  Young Hak Kim,et al.  Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer , 2016, Molecular Cancer Therapeutics.

[16]  P. Li,et al.  Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations. , 2016, Lung cancer.

[17]  C. Paweletz,et al.  Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. , 2016, Cancer discovery.

[18]  P. Stephens,et al.  Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Jeffrey W. Clark,et al.  Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  P. Jänne,et al.  MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T. Mitsudomi,et al.  MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. , 2015, Lung cancer.

[22]  Sheryl K Elkin,et al.  Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation. , 2015, Clinical lung cancer.

[23]  P. Ma.  MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker. , 2015, Cancer discovery.

[24]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[25]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[26]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[27]  Mari Mino-Kenudson,et al.  Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.

[28]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[29]  Levi A Garraway,et al.  Circumventing cancer drug resistance in the era of personalized medicine. , 2012, Cancer discovery.

[30]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[31]  Carmen Birchmeier,et al.  Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.

[32]  I. Okamoto,et al.  MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  Joseph Schoepfer,et al.  A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. , 2011, Cancer research.

[34]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[35]  Y. Yatabe,et al.  Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  Delong Liu,et al.  P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia , 2008, Journal of hematology & oncology.

[37]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[38]  Ravi Salgia,et al.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.

[39]  J. Christensen,et al.  A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. , 2003, Cancer research.

[40]  H. Band,et al.  Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. , 2001, Molecular cell.

[41]  N. Horiya,et al.  Mutations induced in male germ cells after treatment of transgenic mice with ethylnitrosourea. , 1997, Mutation research.

[42]  C. Cooper,et al.  Molecular cloning of a new transforming gene from a chemically transformed human cell line , 1984, Nature.

[43]  B. Taylor,et al.  Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. , 2017, Cancer discovery.

[44]  S. Ou,et al.  Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[45]  S. Ou,et al.  The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. , 2017, Lung cancer.

[46]  R. Roskoski.  Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. , 2016, Pharmacological research.

[47]  Somasekar Seshagiri,et al.  Somatic mutations lead to an oncogenic deletion of met in lung cancer. , 2006, Cancer research.